Royal Philips has won clearance from the U.S. Food and Drug Administration (FDA) for its new Rembra platform— in a significant push into faster, more connected imaging and cancer treatment workflows.
The platform includes three systems—Rembra CT, Rembra RT, and Areta RT—designed to help hospitals handle surging imaging demand and increasingly complex cases without sacrificing diagnostic accuracy.
Healthcare providers worldwide are under mounting pressure as imaging volumes climb and cases grow more complicated. Philips is betting its newly cleared systems can ease that strain by accelerating scan times, improving workflow efficiency, and expanding access to high-quality imaging.
The Rembra platform also broadens the role of CT technology, linking diagnostic radiology with radiation therapy. The goal: a more seamless care pathway, from emergency assessments to highly targeted cancer treatment planning.
“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions,” said Dan Xu, Business Leader of CT at Philips.
“With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”
At the center of the launch is Rembra CT, built for high-pressure clinical environments.
Featuring an industry-leading 85 cm bore, the system is engineered for rapid, high-volume use—capable of handling up to 270 exams per day—making it suited for emergency departments, critical care, and interventional settings. Its advanced imaging capabilities aim to deliver fast results without compromising clarity, a critical factor in urgent medical decisions.
Meanwhile, Rembra RT and Areta RT bring similar performance gains into radiation therapy, where precision is paramount. With a wide field of view and next-generation 4DCT imaging, the systems are designed to improve tumor targeting while minimizing damage to surrounding healthy tissue.
They also streamline simulation and planning workflows, reducing variability and enabling more personalized cancer treatment.
Together, the Rembra platform represents Philips’ push toward a unified imaging ecosystem—one that connects urgent diagnosis with precision-guided therapy. As hospitals grapple with rising demand, the company is positioning its latest technology as a way to deliver faster, more consistent, and more confident care across the entire patient journey.
